In the 2019 Ministerial Declaration, adopted by the CND at its 62nd session, Member States committed to accelerating, based on the principle of common and shared responsibility, the full implementation of the 2009 Political Declaration and Plan of Action, the 2014 Joint Ministerial Statement and the 2016 UNGASS outcome document, aimed at achieving all commitments, operational recommendations and aspirational goals set out therein.
In the stocktaking part of the declaration, Member States identified a number of challenges to the effective implementation of the international drug policy commitments. Based on the identified challenges, the Commission adopted in June 2019 a multi-year workplan to discuss, during annual inter-sessional thematic sessions, how these challenges can be addressed through effectively implementing the provisions contained in the 2016, 2014 and 2009 documents.
Member States further resolved to review in the CND in 2029 the progress in the implementation of all international drug policy commitments, with a mid-term review in 2024.
A core part of the Commission-led follow-up process are annual thematic discussions that are focused on the exchange of good practices, challenges and lessons learned in the implementation of all international drug policy commitments.
For the period 2019-2022, there are meetings of 2 to 3 days every year which would focus on specific challenges as identified in the work plan.
For 2023, immediately preceding the mid-term review, there would be a comprehensive stock-taking of progress made in implementing all international drug policy commitments to address the challenges identified in the Ministerial Declaration.
The 2019 Ministerial Declaration Follow-up Portal, launched at the CND 66th session in March 2023, compiles the statements and presentations made by Member States and other stakeholders during the thematic discussions from 2019 onwards.
E/CN.7/2024/CRP.1 Chair’s summary on the thematic discussions on the implementation of all international drug policy commitments, following-up to the 2019 Ministerial Declaration (23 – 25 October 2023; 4 - 6 December 2023)
E/CN.7/2023/CRP.1 Chair’s summary on the thematic discussions on the implementation of all international drug policy commitments, following-up to the 2019 Ministerial Declaration (21 – 22 September 2022)
E/CN.7/2022/CRP.1 Chair’s summary on the thematic discussions on the implementation of all international drug policy commitments, following-up to the 2019 Ministerial Declaration (19–21 October 2021)
E/CN.7/2021/CRP.1 Chair’s summary on the thematic discussions on the implementation of all international drug policy commitments, following-up to the 2019 Ministerial Declaration (19–21 October 2020)
E/CN.7/2020/CRP.1 Chair's summary by H.E. Ambassador Mirghani Abbaker Altayeb Bakhet (Sudan), Chair of the sixty-second session of the Commission on Narcotic Drugs, on the thematic discussions on the implementation of all international drug policy commitments, following-up to the 2019 Ministerial Declaration (16-18 October 2019)
o both the range of drugs and drugs markets are expanding and diversifying;
o the abuse, illicit cultivation and production and manufacture of narcotic drugs and psychotropic substances, as well as the illicit trafficking in those substances and in precursors, have reached record levels, and that the illicit demand for and the domestic diversion of precursor chemicals are on the rise;
o synthetic opioids and the non-medical use of prescription drugs pose increasing risks to public health and safety, as well as scientific, legal and regulatory challenges, including with regard to the scheduling of substances;
Challenges under discussion:
o increasing links between drug trafficking, corruption and other forms of organized crime, including trafficking in persons, trafficking in firearms, cybercrime and money-laundering and, in some cases, terrorism, including money-laundering in connection with the financing of terrorism, are observed;
o the value of confiscated proceeds of crime related to money-laundering arising from drug trafficking at the global level remains low; and
o the criminal misuse of information and communications technologies for illicit drug-related activities is increasing.
o both the range of drugs and drugs markets are expanding and diversifying;
o the abuse, illicit cultivation and production and manufacture of narcotic drugs and psychotropic substances, as well as the illicit trafficking in those substances and in precursors, have reached record levels, and that the illicit demand for and the domestic diversion of precursor chemicals are on the rise;
o synthetic opioids and the non-medical use of prescription drugs pose increasing risks to public health and safety, as well as scientific, legal and regulatory challenges, including with regard to the scheduling of substances;
